Bendamustine HCl (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending
Bendamustine HCl (Bendamustine HCl) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 6 AB generics, $2.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Multi-Source Generic Manufacturers |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $2.8M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $802K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 1.5% 2-yr change) |